

Vitamin D Endocrine System and Psoriasis Vulgaris – Review of the Literature

Ivana Ručević¹, Vladimira Barišić-Druško², Ljubica Glavaš-Obrovac³,
Mario Štefanić³

¹Private Practice in Dermatology and Venereology; ²Retired Professor of Dermatology and Venereology; ³Department of Nuclear Medicine and Radiation Protection, Osijek University Hospital, Osijek, Croatia

Corresponding author:

Ivana Ručević, MD, PhD
Private Practice in Dermatology and
Venereology
Školska 2
HR-31000 Osijek, Croatia
ivana.rucevic2@os.t-com.hr

Received: March 3, 2009

Accepted: July 20, 2009

SUMMARY Vitamin D exerts its physiological functions on calcium and bone metabolism in humans through the active metabolite 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃). The other spectrum of vitamin D activities includes important effects on cellular proliferation, differentiation and the immune system. These effects are mediated through the intracellularly located vitamin D receptor (VDR). VDR is a member of the steroid, estrogen and retinoid receptor gene family of proteins that mediate transcriptional activities of the respective ligands. The VDR complex binds in the nucleus to the vitamin D responsive element on the gene. Several polymorphisms of the vitamin D receptor (VDR) gene have been described including *FokI* in exon 2, *BsmI* and *ApaI* in intron 8 and *TaqI* in exon 9. Alterations in vitamin D-1,25 (OH)₂D₃ levels and polymorphisms of VDR gene have been shown to be associated with several malignant or autoimmune diseases such as sclerosis multiplex, breast cancer, diabetes mellitus, malignant melanoma, and psoriasis vulgaris. The effects of VDR gene polymorphisms including immunomodulation, stimulation of cellular differentiation and inhibition of proliferation make it a possible candidate for therapy of psoriasis as well as for the psoriasis gene modification. The objective of this article is to present the state-of-the-art in the VDR gene polymorphism research in psoriasis vulgaris.

KEY WORDS: vitamin D receptor gene, polymorphisms, psoriasis

The vitamin D endocrine system is central to the control of bone and calcium homeostasis. However, vitamin D has also been shown to play an important role in other metabolic pathways such as immune response and cancer (1).

VITAMIN D METABOLISM

Vitamin D₃ is a fat-soluble prehormone, which plays an important role in many biologic functions throughout the body. Two thirds of the vitamin D₃ content of the human body are synthesized from the precursor molecule 7-dehydrocholesterol in

the skin by the action of sunlight, and one third is obtained from diet (2).

After UVB exposure, vitamin D₃ enters blood circulation and binds to the vitamin D binding protein (DBP) (3), which carries vitamin D₃ to the liver and kidney (4) for bioactivation. In the first activation step, vitamin D₃ is hydroxylated by the enzyme 25-hydroxylase to 25-hydroxyvitamin D₃ (25OHD₃), mainly in the liver. In the second step, the biologically active hormone 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) is generated by hydroxylation of 25OHD₃. This reaction is catalyzed by the enzyme 25-hydroxyvitamin D₃-1- α -hydroxylase (1- α -hydroxylase) and it occurs mainly in the kidney (5). The active hormone stays in blood circulation for about 7 hours. As a fat soluble molecule, 1,25(OH)₂D₃ penetrates easily the plasma membrane of its target cells, where it is catabolized (6).

ACTIONS OF VITAMIN D

The 1,25(OH)₂D₃ regulates several functions in the body by modulating genomic events *via* its nuclear receptor. Classically, the main role of 1,25(OH)₂D₃ is regulation of serum calcium and phosphorus concentrations *via* actions in bone, parathyroid gland, kidney and intestine, which are considered as classic target organs for 1,25(OH)₂D₃. In addition, 1,25(OH)₂D₃ is able to generate several other biologic responses (non-classic actions of vitamin D) that are not related to the control of mineral homeostasis. Today, there are over 30 non-classic target tissues for 1,25(OH)₂D₃ (7).

In addition to the genomic actions, 1,25(OH)₂D₃ is also able to generate rapid biologic responses, which do not require any protein synthesis as genomic actions do (8). There is also evidence that rapid responses are able to modulate the genomic pathway of 1,25(OH)₂D₃ actions *via* phosphorylation of nuclear vitamin D receptor (VDR). Receptor phosphorylation could increase the affinity of VDR to coactivator complexes and thus enhance gene activation (9).

Immunomodulatory effects

Vitamin D₃ is an important immunomodulatory hormone that activates monocytes, stimulates

cell-mediated immunity, influences cytokine synthesis and suppresses lymphocyte proliferation (10). VDR and 1,25(OH)₂D₃ play a role in the Th1/Th2 balance through transcriptional inhibition of cytokine genes that are either required for Th1 differentiation or are products of differentiated Th1 cells. Active 1,25(OH)₂D₃ has been found to inhibit Th1 cytokines interferon gamma (IFN- γ) and interleukin-2 (IL-2), suppressing the production of pro-Th1 cytokine IL-12 by antigen presenting cells. 1,25(OH)₂D₃ has also been reported to increase Th2 cytokine IL-4 (11). In dendritic cells, calcitriol suppresses the expression of major histocompatibility complex (MHC) class II molecules and costimulatory molecules including CD40, CD80 and CD86, stimulates the production of IL-10 and inhibits the production of IL-12, leading to the suppression of T cell activation (12).

VITAMIN D RECEPTOR

The genomic actions of 1,25(OH)₂D₃ are mediated by its nuclear receptor, whose cDNA was first cloned from chicken in 1987 and shortly thereafter from human (13). VDR protein is a nuclear hormone receptor (NHR), a member of the steroid, estrogen, and retinoid receptor gene family of proteins, mediating the action of 1,25(OH)₂D₃ by controlling the expression of hormone sensitive genes (14). The VDR complex binds in the nucleus to the vitamin D responsive element in regulatory regions of target genes and changes the gene transcription (15). It is found on the cells of many different tissues, including the thyroid, bone, kidney and T cells of the immune system (16).

In humans, VDR protein consists of 427 amino acids, with a molecular mass of ~48 kDa. Like other NHRs, VDR can be divided by function into several domains. At the amino terminus there is an A/B domain 20 amino acids long. The DNA-binding domain (DBD), also termed C domain, locates between amino acids 21 and 92. The D or flexible linker region locates approximately between amino acids 93 and 123, followed by the E or ligand binding domain (LBD) between amino acids 124 and 427 (Fig. 1) (15).

Skin cells (keratinocytes, fibroblasts and other cells) express VDR. The presence of this receptor has been examined in human skin and in cultures




Figure 1. Schematic presentation of vitamin D receptor domain structure (A/B domain; DBD or DNA, binding domain; D or flexible linker region; E or ligand binding domain, LBD).

of human epidermal keratinocytes and human dermal fibroblasts (17). Immunohistochemical studies of normal skin have shown VDR antigens to be expressed in keratinocytes of all epidermal layers (except those of the stratum corneum) and in cells of epidermal appendages. Some 50%-65% of Langerhans' cells, monocytes, and T-lymphocytes in the normal skin express VDR (18).

VDR gene

The human vitamin D receptor gene (*hVDR*) is a product of the single chromosomal gene, which is found on chromosome 12, localized to 12q13.11, and spans 75 kb, covering 62 359 base pairs (bp). The *hVDR* consists of eleven exons, of which the 5' non-coding region contains three exons (1A, 1B, and 1C) and the remaining eight exons (exons 2-9) encode the structural portion of the VDR gene product. Promoters for the *hVDR* are found in exons 1F, 1A and 1D. They do not contain a TATA-box, although they are GC rich. This region causes differential splicing of transcripts. Three VDR mRNA transcripts are synthesized depending on how exons 1A, 1B, and 1C are spliced to form a mature mRNA transcript from which VDR protein can be translated (1,19).

VDR polymorphisms

Polymorphism is a genetic variant that appears in at least 1% of the population. These changes can occur in non-coding parts of the gene (introns), and they would not be seen in the protein product. However, changes in the exonic parts of the DNA lead to changes in protein sequence.

More than 25 polymorphisms are currently known for the *VDR* locus. These occur mostly near the 3' end but also towards the 5' end, in and near the promoter region (Fig. 2). More than 10 known polymorphisms exist in the 3' UTR including a poly(A) repeat polymorphism. Other single nucleotide polymorphisms (SNPs) in the *VDR* include the G to A polymorphism in the binding element of *Cdx-2* (exon 1E) as well as the functional *FokI* polymorphism in exon II. The SNPs *BsmI* and *Apal* in intron VIII, *TaqI* in exon IX and the poly(A)

repeat polymorphism in the 3' UTR within exon IX is located in an island of linkage disequilibrium (LD) forming haplotype alleles (20).

The *Cdx-2* polymorphism in the promoter region of the *hVDR* gene lies close to the SNP found in the center of exon II (*FokI*). *Cdx-2* plays a crucial role in intestine-specific *VDR* gene expression, as it is able to activate *VDR* gene transcription. (21).

The *FokI* polymorphism (alleles F/f corresponding to nucleotides C/T) is found in this exon and increases the overall length of the *VDR* transcript by 9 bp. While the *FokI* polymorphism is the most credible candidate for a functional change, *FokI* might be a marker for a nearby functional polymorphism within the *VDR* or nearby gene (22).

The 3'-end of the gene is particularly rich in polymorphisms. The *Tru9I* (TR/tr corresponding to nucleotides G/A) (23), *BsmI* (B/b corresponding to nucleotides G/A) (24), and *Apal* (A/a corresponding to nucleotides T/G) (25) polymorphisms are located in intron VIII, and are in strong LD with each other and with the silent *TaqI* polymorphism (T/t corresponding to nucleotides T/C) found in exon IX (26). Although the *BsmI* and *Apal* loci are intronic, a number of mechanisms have been invoked to explain how these polymorphisms might influence the expression of VDR. One of these explanations includes disruption of the splice site for *VDR* mRNA transcription, which may result in truncated or alternatively spliced protein products. Another explanation involves changes in mRNA stability speculating that these introns might influence the level of mRNA product (27).

More than 10 different sequence variants in the 3'-end untranslated region (UTR) have been described, including the poly(A) repeat polymorphism (27). The poly(A) polymorphism consists of variations in the number of the adenosine residues repeated. Ingles *et al.* (28) broadly divided a stretch of 17 poly-A's as the short (S) allele and ≥ 18 poly-A's as the long (L) allele. This L/S polymorphism is in LD with the *BsmI*, *Apal* and *TaqI* polymorphisms in intron VIII and exon IX, although LD differs between populations. The *TaqI* polymorphism results in a silent mutation in exon 9,




Figure 2. Vitamin D receptor polymorphisms.

with ATT and ATC both coding for isoleucine. LD between *BsmI*, *Apal* and *TaqI* has led to various haplotype studies involving these polymorphisms (29).

VDR gene polymorphisms and psoriasis vulgaris

Psoriasis is a common, chronic inflammatory and hyperproliferative skin disease. Clinical lesions are results of hyperproliferation and abnormal differentiation of keratinocytes and epidermis infiltration with inflammatory cells including T cells and neutrophils. The etiology of psoriasis involves genetic, immune and environmental factors. In addition to the association with HLA gene on chromosome 6q21, other genes are also included in the disease onset (30). Previous studies on psoriasis and VDR gene have demonstrated both non-significant and significant associations, however, with different polymorphisms involved (31-39).

In addition to the classic action on calcium homeostasis and bone metabolism, calcipotriol inhibits proliferation and induces terminal differentiation of keratinocytes. It has been reported that cultured fibroblasts and keratinocytes from psoriatic patients exhibit partial resistance to calcipotriol mediated anti-proliferative activity, and response to calcipotriol treatment has been shown to vary among these patients (40).

VDR gene polymorphisms may explain this variable responsiveness. There have been a number of studies to investigate whether VDR gene polymorphisms could be a risk factor for the development of psoriasis in different populations.

It is known that VDR genotype distribution varies dramatically due to ethnic composition and genetic background of the population, and sample size (31). Some studies have reported a correlation between individual VDR genotypes (*BsmI*, *TaqI*, *Apal* or *FokI*) and skin eruptions or efficacy of treatment with vitamin D analog (35).

Park *et al.* have reported a significantly higher frequency of the A allele by *Apal* in psoriatics than in healthy controls, and the tendency was more accentuated in early-onset psoriasis. They also report a significant association between VDR genotype and mean age at onset. The authors suggest that VDR gene might be one the candidate genes implicated in the pathogenesis of psoriasis in the Korean population (31).

Okita *et al.* studied allelic frequencies of VDR in 86 normal subjects and 50 psoriatics. All subjects enrolled in this study were Japanese. The

frequencies of *Apal*, *BsmI* and *TaqI* genotypes in psoriatics showed no significant differences compared with control subjects. The distribution of *Apal*, *BsmI* and *TaqI* VDR genotypes showed no significant relationship to the PASI score or age at onset (32).

In another study from Japan, the frequency of TT genotype was found to be higher in patients than in control (87% vs. 74%; $P < 0.05$). They also showed that B allele and t allele were lower in patients than in controls. They found the VDR gene polymorphisms to be associated with psoriasis in Japanese patients (33).

Two related studies were conducted in Turkey. Kaya *et al.* investigated the association between VDR gene polymorphisms and psoriasis in Turkish patients. They demonstrated an association between aa/AA genotypes and 53 psoriasis patients compared to 54 healthy controls (AA: 26.4% vs. 50%; Aa: 58.5% vs. 38.9%; and aa: 15.1% vs. 11%) (34).

In contrast, Dayangac-Erden *et al.* showed that there was no significant difference in *Apal* polymorphisms between Turkish patients and controls (AA: 23.5% vs. 30%; Aa: 56.9% vs. 55%; aa: 19.6% vs. 15%; $P \leq 1$). However, in the study population consisting of 51 Turkish familial psoriasis patients (psoriasis vulgaris and psoriatic arthritis) and 100 healthy subjects, the frequency of TT genotype was found to be significantly higher in patients than in controls (73.5% vs. 59.5%; $P \leq 0.025$). In psoriatic arthritis patients, the frequency of T allele was even higher (91.7%; $P \leq 0.05$). The authors conclude that VDR gene *TaqI* polymorphisms are associated with familial psoriasis in the Turkish population. The authors explain the discrepancy of these results by the heterogeneous genetic composition of their study subjects examined at Hacettepe University in central Turkey (35).

In the latest related study in Europe, performed by Ruggiero *et al.*, found the VDR gene polymorphisms not to be associated with psoriasis in the Italian Caucasian population (39). The role of VDR polymorphism analysis in predicting clinical response to calcipotriol was investigated in only a few studies, with controversial results (33,36-38).

In conclusion, the discrepancy of results reported from studies on VDR gene polymorphisms (onset or therapy of disease) might be explained by 1) genetically different populations; 2) size of the population samples; and 3) therapeutic response to different therapeutic agents administered in different concentrations. It should be noted that most

of these studies included small numbers of subjects, which could be the main reason for conflicting results.

Acknowledgment. This work was financially supported by the Ministry of Science, Education and Sports of the Republic of Croatia (No. 219-2190372-2068).

References

1. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, *et al.* The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. *J Bone Miner Res* 1998;13:325-49.
2. Holick MF. Vitamin D: a millennium perspective. *J Cell Biochem* 2003;88:296-307.
3. Haddad JG, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J. Human plasma transport of vitamin D after its endogenous synthesis. *J Clin Invest* 1993;91:2552-5.
4. Wikvall K. Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form. *Int J Mol Med* 2001;7:201-9.
5. Okuda K, Usui E, Ohyama Y. Recent progress in enzymology and molecular biology of enzymes involved in vitamin D metabolism. *J Lipid Res* 1995;36:1641-52.
6. Dusso AS, Negrea L, Gunawardhana S, Lopez-Hilker S, Finch J, Mori T, *et al.* On the mechanisms for the selective action of vitamin D analogs. *Endocrinology* 1991;128:1687-92.
7. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. *Endocr Rev* 1995;16:200-57.
8. Norman AW, Song X, Zanello L, Bula C, Okamura WH. Rapid and genomic biological responses are mediated by different shapes of the agonist steroid hormone 1 α ,25(OH) $_2$ vitamin D $_3$. *Steroids* 1999;64:120-8.
9. de Boland AR, Boland RL. Non-genomic signal transduction pathway of vitamin D in muscle. *Cell Signal* 1994;6:717-24.
10. Manolagas SC, Wertz DA, Tsoukas CD, Provvedini DM, Vaughan JH. 1,25-Dihydroxyvitamin D $_3$ receptors in lymphocytes from patients with rheumatoid arthritis. *J Lab Clin Med* 1986;108:596-600.
11. Larsen CG, Kristensen M, Paludan K, Deleuran B, Thomsen MK, Zachariae C, *et al.* 1,25(OH) $_2$ -D $_3$ is a potent regulator of interleukin-1 induced interleukin-8 expression and production. *Biochem Biophys Res Commun* 1991;176:1020-6.
12. Van Etten E, Decallone B, Verlinden L, Verstuyf A, Bouillon R, Mathieu C. Analogs of 1 α ,25-dihydroxyvitamin D $_3$ as pluripotent immunomodulators. *J Cell Biochem* 2003;88:223-6.
13. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, *et al.* Cloning and expression of full-length cDNA encoding human vitamin D receptor. *Proc Natl Acad Sci USA* 1988;85:3294-8.
14. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. *Mol Cell Biol* 2003;23:277-300.
15. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. *Physiol Rev* 1998;78:1193-231.
16. DeLuca HF, Zierold C. Mechanisms and functions of vitamin D. *Nutr Rev* 1998;56:4-10.
17. Feldman D, Chen T, Hirst M, Colston K, Karasek M, Cone C. Demonstration of 1,25-dihydroxyvitamin D $_3$ receptors in human skin biopsies. *J Clin Endocrinol Metab* 1980;51:1463-5.
18. Milde P, Hauser U, Simon T, Mall G, Ernest V, Haussler MR, *et al.* Expression of 1,25-dihydroxyvitamin D $_3$ receptors in normal and psoriatic skin. *J Invest Dermatol* 1991;97:230-9.
19. Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, *et al.* Structural organization of the human vitamin D receptor chromosomal gene and its promoter. *Mol Endocrinol* 1997;11:1165-79.
20. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. *Gene* 2004;338:143-56.
21. Yamamoto H, Miyamoto K, Li B, Taketani Y, Kitano M, Inoue Y, *et al.* The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. *J Bone Miner Res* 1999;14:240-7.
22. Arai H, Miyamoto K, Taketani Y, Yamamoto H, Iemori Y, Morita K, *et al.* A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. *J Bone Miner Res* 1997;12:915-21.
23. Ye WZ, Reis AF, Velho G. Identification of no-

- vel Tru9 I polymorphism in the human vitamin D receptor gene. *J Hum Genet* 2000;45:56-7.
24. Morrison NA, Yeoman R, Kelly PJ, Eisman JA. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. *Proc Natl Acad Sci USA* 1992;89:6665-9.
 25. Faraco JH, Morrison NA, Baker A, Shine J, Frossard PM. Apal dimorphism at the human vitamin D receptor gene locus. *Nucleic Acids Res* 1989;17:2150.
 26. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, *et al.* Prediction of bone density from vitamin D receptor alleles. *Nature* 1994;367:284-7.
 27. Whitfield GK, Remus LS, Jurutka PW, Zitzer H, Oza AK, Dang HT, *et al.* Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. *Mol Cell Endocrinol* 2001;177:145-59.
 28. Ingles SA, Haile RW, Henderson BE, Kolonel LN, Nakaichi G, Shi CY, *et al.* Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. *Cancer Epidemiol Biomarkers Prev* 1997;6:93-8.
 29. Zmuda JM, Cauley JA, Ferrell RE. Molecular epidemiology of vitamin D receptor gene variants. *Epidemiol Rev* 2000;22:203-17.
 30. Jullien D, Barker JN. Genetics of psoriasis. *J Eur Acad Dermatol Venereol* 2006;20(Suppl. 2):42-51.
 31. Park BS, Park JS, Lee DY, Youn JI, Kim IG. Vitamin D receptor polymorphism is associated with psoriasis. *J Invest Dermatol* 1999;112:113-6.
 32. Okita H, Ohtsuka T, Yamakage A, Yamazaki S. Polymorphism of the vitamin D(3) receptor in patients with psoriasis. *Arch Dermatol Res* 2002;294:159-62.
 33. Saeki H, Asano N, Tsunemi Y, Takekoshi T, Kishimoto M, Mitsui H, *et al.* Polymorphisms of vitamin D receptor gene in Japanese patients with psoriasis vulgaris. *J Dermatol Sci* 2002;30:167-71.
 34. Kaya TI, Erdal ME, Tursen U, Camdeviren H, Gunduz O, Soylemez F, *et al.* Association between vitamin D receptor gene polymorphism and psoriasis among Turkish population. *Arch Dermatol Res* 2002;294:286-9.
 35. Dayangac-Erden D, Karaduman A, Erdem-Yurter H. Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. *Arch Dermatol Res* 2007;299:487-91.
 36. Halsall JA, Osborne JE, Pringle JH, Hutchinson PE. Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. *Pharmacogenet Genomics* 2005;15:349-55.
 37. Lee DY, Park BS, Choi KH, Jeon JH, Cho KH, Song KY, Kim IG, Youn JI. Vitamin D receptor genotypes are not associated with clinical response to calcipotriol in Korean psoriasis patients. *Arch Dermatol Res* 2002;294:1-5.
 38. Kontula K, Valimaki S, Kainulainen K, Viitainen AM, Keski-Oja J. Vitamin D receptor polymorphism and treatment of psoriasis with calcipotriol. *Br J Dermatol* 1997;136:977-8.
 39. Ruggiero M, Gulisano M, Peruzzi B, Giomi B, Caproni M, Fabbri P, Pacini S. Vitamin D receptor gene polymorphism is not associated with psoriasis in the Italian Caucasian population. *J Dermatol Sci* 2004;35:68-70.
 40. Smith EL, Walworth NC, Holick MF. Effect of 1 alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. *J Invest Dermatol* 1986;86:709-14.